177036-94-1 | (2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

Packsize	Purity	Availability	Price	Discounted Price
20mg	98%	in stock	$32.00	$22.00
100mg	98%	in stock	$89.00	$63.00
1g	98%	in stock	$137.00	$96.00
5g	98%	in stock	$386.00	$270.00
10g	98%	in stock	$665.00	$466.00
25g	98%	in stock	$1,317.00	$922.00

Description

• Catalog Number: AA99691
• Chemical Name: (2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
• CAS Number: 177036-94-1
• Molecular Formula: C22H22N2O4
• Molecular Weight: 378.4211
• MDL Number: MFCD09842330
• SMILES: COC([C@@H](C(=O)O)Oc1nc(C)cc(n1)C)(c1ccccc1)c1ccccc1

Computed Properties

• Complexity: 475
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 3.8

Literature

• Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.

  Reproductive toxicology (Elmsford, N.Y.) 20150815

• Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.

  Current medical research and opinion 20150101

• AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension.

  Global cardiology science & practice 20150101

• Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults.

  International journal of clinical pharmacology and therapeutics 20141101

• Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.

  European journal of clinical pharmacology 20131001

• Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.

  Journal of clinical pharmacology 20121201

• Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.

  The American journal of cardiology 20121101

• Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.

  Expert opinion on drug safety 20121101

• Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways.

  Life sciences 20121015

• Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.

  Life sciences 20121015

• Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.

  Life sciences 20121015

• The combination of theophylline and endothelin receptor antagonism improves exercise performance of rats under simulated high altitude.

  Journal of applied physiology (Bethesda, Md. : 1985) 20121015

• LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study.

  Biomedical chromatography : BMC 20121001

• Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.

  Journal of the American College of Cardiology 20120703

• Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.

  Current medical research and opinion 20120601

• Treatment of pulmonary arterial hypertension in connective tissue disease.

  Drugs 20120528

• Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120515

• Chronic endothelin A receptor blockade attenuates contribution of sympathetic nervous system to salt hypertension development in adult but not in young Dahl rats.

  Acta physiologica (Oxford, England) 20120501

• Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics.

  International journal of cardiology 20120419

• Endothelin-1 promotes cytoplasmic accumulation of RIP140 through a ET(A)-PLCβ-PKCε pathway.

  Molecular and cellular endocrinology 20120404

• ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

  Cardiovascular therapeutics 20120401

• eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype.

  Journal of the American Society of Nephrology : JASN 20120401

• Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode.

  Journal of separation science 20120401

• Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

  The AAPS journal 20120301

• Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.

  Hypertension (Dallas, Tex. : 1979) 20120301

• Synthesis of (+)-ambrisentan via chiral ketone-catalyzed asymmetric epoxidation.

  The Journal of organic chemistry 20120106

• Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

  Chest 20120101

• Inhaled treprostinil: a therapeutic review.

  Drug design, development and therapy 20120101

• Pulmonary arterial hypertension: advances in pathophysiology and management.

  Indian journal of pharmacology 20120101

• A novel expression of exercise induced pulmonary hypertension in human immunodeficiency virus patients: a pilot study.

  The open cardiovascular medicine journal 20120101

• Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

  Journal of medical economics 20120101

• Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension.

  PloS one 20120101

• Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

  PloS one 20120101

• Pulmonary arterial hypertension: an update.

  Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111201

• [Treatment of pulmonary fibrosis. New substances and new interventions].

  Der Internist 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.

  Postgraduate medicine 20111101

• Macitentan: entry-into-humans study with a new endothelin receptor antagonist.

  European journal of clinical pharmacology 20111001

• Endothelin receptor antagonists -- their role in pulmonary medicine.

  Revue des maladies respiratoires 20111001

• Ambrisentan for sarcoidosis associated pulmonary hypertension.

  Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 20111001

• Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.

  Current medical research and opinion 20110901

• Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.

  Zeitschrift fur Gastroenterologie 20110901

• Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.

  Hematology reports 20110831

• Ambrisentan.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801

• Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.

  The American journal of cardiology 20110715

• Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.

  Expert opinion on pharmacotherapy 20110701

• Synthesis and in vitro evaluation of ambrisentan analogues as potential endothelin receptor antagonists.

  Bioorganic & medicinal chemistry letters 20110701

• [Treatment of idiopathic pulmonary arterial hypertension].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20110701

• Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.

  European journal of pharmacology 20110625

• New perspectives for the treatment of pulmonary hypertension.

  British journal of pharmacology 20110501

• Novel therapeutic approaches for pulmonary fibrosis.

  British journal of pharmacology 20110501

• Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.

  The American journal of cardiology 20110501

• With REMS, what goes up can come down.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110501

• Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension.

  Angiogenesis 20110301

• Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.

  Internal medicine journal 20110301

• Pharmacokinetic evaluation of ambrisentan.

  Expert opinion on drug metabolism & toxicology 20110301

• Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.

  Journal of gastrointestinal and liver diseases : JGLD 20110301

• [Changes long term prognosis of 17 patients with pulmonary artery hypertension].

  Revista medica de Chile 20110301

• Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

  Inflammation & allergy drug targets 20110201

• Effects of multiple doses of ambrisentan on the pharmacokinetics of a single dose of digoxin in healthy volunteers.

  Journal of clinical pharmacology 20110101

• Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.

  Chest 20110101

• Identification of clinically used drugs that activate pregnane X receptors.

  Drug metabolism and disposition: the biological fate of chemicals 20110101

• Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

  PharmacoEconomics 20110101

• Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.

  Vascular health and risk management 20110101

• Pulmonary vascular complications of chronic liver disease: Pathophysiology, imaging, and treatment.

  Annals of thoracic medicine 20110101

• Short term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial.

  BMC pulmonary medicine 20110101

• [Pulmonary arterial hypertension: changing approaches to management].

  Kardiologiia 20110101

• Recent trends in pulmonary arterial hypertension.

  Lung India : official organ of Indian Chest Society 20110101

• Therapeutic strategies in pulmonary hypertension.

  Frontiers in pharmacology 20110101

• Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice.

  Arthritis research & therapy 20110101

• Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

  Orphanet journal of rare diseases 20110101

• Diagnosis and management of pulmonary arterial hypertension.

  Pulmonary medicine 20110101

• Anaesthesia Management of Caesarean Section in Two Patients with Eisenmenger's Syndrome.

  Anesthesiology research and practice 20110101

• Diagnostic and therapeutic algorithm for pulmonary arterial hypertension.

  Pulmonary circulation 20110101

• Overview of current therapeutic approaches for pulmonary hypertension.

  Pulmonary circulation 20110101

• Vascular involvement in systemic sclerosis (scleroderma).

  Journal of inflammation research 20110101

• Assessment of daily life physical activities in pulmonary arterial hypertension.

  PloS one 20110101

• Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.

  International journal of rheumatology 20110101

• Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.

  BMC pulmonary medicine 20110101

• Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

  Pulmonary medicine 20110101

• Surgical treatment of pulmonary hypertension: Lung transplantation.

  Pulmonary circulation 20110101

• Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management.

  European respiratory review : an official journal of the European Respiratory Society 20101201

• The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results.

  Current cardiology reviews 20101101

• Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.

  Clinical pharmacology and therapeutics 20101001

• Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses.

  European heart journal 20100901

• Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.

  Canadian journal of physiology and pharmacology 20100601

• Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis.

  Medical science monitor : international medical journal of experimental and clinical research 20100501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100501

• [Pulmonary circulation: contributions of the year 2009].

  Archivos de bronconeumologia 20100301

• Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.

  Journal of cardiac failure 20100201

• [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].

  Revue des maladies respiratoires 20100201

• Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.

  Respiratory research 20100101

• Pulmonary arterial hypertension in connective tissue diseases.

  Cardiology in review 20100101

• Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

  BMC cardiovascular disorders 20100101

• Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.

  Applied health economics and health policy 20100101

• Portopulmonary hypertension.

  Annals of thoracic medicine 20100101

• Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study.

  Clinical drug investigation 20100101

• Pharmacotherapeutic management of pulmonary arterial hypertension.

  Cardiology in review 20100101

• The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

  Vascular health and risk management 20100101

• Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.

  Drug design, development and therapy 20100101

• Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan.

  Therapeutics and clinical risk management 20100101

• Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.

  Clinical drug investigation 20100101

• Inhaled treprostinil and pulmonary arterial hypertension.

  Vascular health and risk management 20100101

• Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy.

  Drug, healthcare and patient safety 20100101

• No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

  Journal of pharmaceutical sciences 20091201

• Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.

  British journal of haematology 20091201

• [Endothelin receptor antagonists - their role in pulmonary medicine].

  Revue des maladies respiratoires 20091201

• Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

  Journal of the American College of Cardiology 20091117

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091101

• Can we improve outcome of congenital diaphragmatic hernia?

  Pediatric surgery international 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.

  Expert opinion on pharmacotherapy 20090801

• Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension.

  Korean circulation journal 20090801

• Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

  Journal of clinical pharmacology 20090601

• Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

  Rheumatology (Oxford, England) 20090601

• Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.

  IDrugs : the investigational drugs journal 20090601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090601

• The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.

  British journal of clinical pharmacology 20090501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.

  Prescrire international 20090401

• A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.

  European heart journal 20090201

• Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

  Chest 20090101

• [Pulmonary arterial hypertension: a voyage around the year 2008].

  Archivos de bronconeumologia 20090101

• Pulmonary arterial hypertension in children: a medical update.

  Indian journal of pediatrics 20090101

• Review of inhaled iloprost for the control of pulmonary artery hypertension in children.

  Vascular health and risk management 20090101

• New concepts in the invasive and non invasive evaluation of remodelling of the right ventricle and pulmonary vasculature in pulmonary arterial hypertension.

  The open respiratory medicine journal 20090101

• Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer.

  Oncology research 20090101

• Treatment of pediatric pulmonary hypertension.

  Vascular health and risk management 20090101

• Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.

  Applied health economics and health policy 20090101

• Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.

  Vascular health and risk management 20090101

• Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model.

  Clinical drug investigation 20090101

• Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

  Drug design, development and therapy 20090101

• Therapeutic methods used in patients with Eisenmenger syndrome.

  Cardiology journal 20090101

• Integrated care and optimal management of pulmonary arterial hypertension.

  Journal of multidisciplinary healthcare 20090101

• Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.

  Journal of clinical pharmacology 20081201

• Ambrisentan and its role in the management of pulmonary arterial hypertension.

  Drugs of today (Barcelona, Spain : 1998) 20081201

• Role of ambrisentan in the management of pulmonary hypertension.

  The Annals of pharmacotherapy 20081101

• [Specific drugs for the treatment of pulmonary arterial hypertension - current status].

  Deutsche medizinische Wochenschrift (1946) 20081001

• Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

  Vascular health and risk management 20081001

• Pulmonary arterial hypertension: on the way to a manageable disease.

  Current opinion in investigational drugs (London, England : 2000) 20080901

• Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

  European heart journal 20080801

• [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20080801

• The management of pulmonary hypertension in children.

  Archives of disease in childhood 20080701

• Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

  Circulation 20080610

• The status of pulmonary arterial hypertension in 2008.

  Circulation 20080610

• [Systemic sclerosis].

  Medizinische Monatsschrift fur Pharmazeuten 20080501

• Ambrisentan for the management of pulmonary arterial hypertension.

  Clinical therapeutics 20080501

• [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].

  La Revue de medecine interne 20080401

• The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

  British journal of pharmacology 20080301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080301

• Endothelin receptor antagonists in pulmonary arterial hypertension.

  The European respiratory journal 20080201

• Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management.

  Current cardiology reviews 20080201

• Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20080101

• Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.

  Scandinavian journal of clinical and laboratory investigation 20080101

• Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.

  Drugs 20080101

• Ambrisentan.

  Drugs 20080101

• Pulmonary hypertension: past, present and future.

  Annals of thoracic medicine 20080101

• Ambrisentan for the treatment of pulmonary arterial hypertension.

  Drug design, development and therapy 20080101

• Review of bosentan in the management of pulmonary arterial hypertension.

  Vascular health and risk management 20071201

• Ambrisentan (Letairis) for pulmonary arterial hypertension.

  The Medical letter on drugs and therapeutics 20071022

• Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension.

  International journal of clinical practice 20071001

• Expert opinion on available options treating pulmonary arterial hypertension.

  Expert opinion on pharmacotherapy 20071001

• Ambrisentan.

  Nature reviews. Drug discovery 20070901

• Therapeutic challenges for systemic sclerosis: facts and future targets.

  Annals of the New York Academy of Sciences 20070901

• New drug approved for pulmonary arterial hypertension.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070801

• EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils.

  Brain research 20070709

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• Pathophysiological role of platelets in acute experimental pancreatitis: influence of endothelin A receptor blockade.

  Cell and tissue research 20070301

• Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.

  Clinics in chest medicine 20070301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070301

• A review of pulmonary arterial hypertension: role of ambrisentan.

  Vascular health and risk management 20070201

• Therapeutic targets in systemic sclerosis.

  Arthritis research & therapy 20070101

• New drugs: ambrisentan, temsirolimus, and eculizumab.

  Journal of the American Pharmacists Association : JAPhA 20070101

• [Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].

  Kardiologiia 20070101

• Management of pulmonary arterial hypertension associated with congenital heart disease.

  Romanian journal of internal medicine = Revue roumaine de medecine interne 20070101

• Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.

  Core evidence 20070101

• [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].

  Deutsche medizinische Wochenschrift (1946) 20061208

• Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?

  Current medical research and opinion 20061201

• Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.

  Proceedings of the American Thoracic Society 20060901

• Endothelin receptor antagonists.

  Pharmacology & therapeutics 20060601

• Profile of past and current clinical trials involving endothelin receptor antagonists: the novel '-sentan' class of drug.

  Experimental biology and medicine (Maywood, N.J.) 20060601

• Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin.

  Experimental biology and medicine (Maywood, N.J.) 20060601

• Attenuation of proinflammatory gene expression and microcirculatory disturbances by endothelin A receptor blockade after orthotopic liver transplantation in pigs.

  Surgery 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Ambrisentan, a non-peptide endothelin receptor antagonist.

  Cardiovascular drug reviews 20060101

• Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.

  Nature clinical practice. Rheumatology 20051201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051001

• Ambrisentan therapy for pulmonary arterial hypertension.

  Journal of the American College of Cardiology 20050802

• Ambrisentan for pulmonary arterial hypertension.

  Future cardiology 20050701

• [Emerging therapies for the treatment of pulmonary arterial hypertension].

  Herz 20050601

• [Treatment algorithm for pulmonary arterial hypertension].

  Herz 20050601

• Improvement of postischemic hepatic microcirculation after endothelinA receptor blockade--endothelin antagonism influences platelet-endothelium interactions.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20050201

• Drug treatment of pulmonary arterial hypertension: current and future agents.

  Drugs 20050101

• Effects of ET(A) receptor antagonism on proinflammatory gene expression and microcirculation following hepatic ischemia/reperfusion.

  Microcirculation (New York, N.Y. : 1994) 20050101

• Changes of vasoregulatory gene expression following hepatic ischemia/reperfusion and treatment with endothelin-A receptor blockade.

  Journal of cardiovascular pharmacology 20041101

• Endothelin-A receptor blockade improves postischemic hepatic microhemodynamics.

  Journal of cardiovascular pharmacology 20041101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041001

• Endothelin receptor antagonists in pulmonary arterial hypertension.

  Journal of the American College of Cardiology 20040616

• Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis.

  Langenbeck's archives of surgery 20040601

• Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.

  Journal of medicinal chemistry 20040520

• Influence of a selective endothelin(A) receptor antagonist on the quantitative mRNA expression and the immunohistochemistry of vasoactive mediators after pancreas transplantation.

  Transplantation proceedings 20030901

• Cerebrovascular characterization of the novel nonpeptide endothelin-A receptor antagonist LU 208075.

  Clinical neuropharmacology 20030101

• Ambrisentan (Myogen).

  Current opinion in investigational drugs (London, England : 2000) 20021001

• Administration of a selective endothelin-a receptor antagonist (BSF 208075) improves hepatic warm ischemia/reperfusion injury in pigs.

  Transplantation proceedings 20020901

• Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery.

  Clinical science (London, England : 1979) 20020801

• Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function.

  Clinical science (London, England : 1979) 20020801